A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia - Concepedia

Concepedia

Publication | Open Access

A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia

DOI Full Paper Access

30

Citations

23

References

2016

Year

Megan Bohensky, Kumar Pasupathi, Alexandra Gorelik, Hansoo Kim, James P. Harrison, Danny Liew

Value in Health

Surgical OncologyCost-effectiveness AnalysisOncologyCancer ManagementMelanomaNivolumab ComparedImmune Checkpoint InhibitorDermatologyMedicineSkin Cancer

References

	Year	Citations

Page 1